PL2215047T3 - Sposób leczenia niedoborów witaminy b12 - Google Patents

Sposób leczenia niedoborów witaminy b12

Info

Publication number
PL2215047T3
PL2215047T3 PL08844673T PL08844673T PL2215047T3 PL 2215047 T3 PL2215047 T3 PL 2215047T3 PL 08844673 T PL08844673 T PL 08844673T PL 08844673 T PL08844673 T PL 08844673T PL 2215047 T3 PL2215047 T3 PL 2215047T3
Authority
PL
Poland
Prior art keywords
deficiency
treating vitamin
vitamin
treating
Prior art date
Application number
PL08844673T
Other languages
English (en)
Polish (pl)
Inventor
Cristina Castelli
Laura Kragie
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2215047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of PL2215047T3 publication Critical patent/PL2215047T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08844673T 2007-11-02 2008-10-31 Sposób leczenia niedoborów witaminy b12 PL2215047T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US2010808P 2008-01-09 2008-01-09
US8356608P 2008-07-25 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency
EP08844673.7A EP2215047B1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (1)

Publication Number Publication Date
PL2215047T3 true PL2215047T3 (pl) 2014-05-30

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08844673T PL2215047T3 (pl) 2007-11-02 2008-10-31 Sposób leczenia niedoborów witaminy b12

Country Status (18)

Country Link
US (3) US8022048B2 (OSRAM)
EP (1) EP2215047B1 (OSRAM)
JP (1) JP5555634B2 (OSRAM)
KR (1) KR101344369B1 (OSRAM)
CN (1) CN101952241B (OSRAM)
AU (1) AU2008318423B2 (OSRAM)
BR (1) BRPI0817396C8 (OSRAM)
CA (1) CA2704780C (OSRAM)
CL (1) CL2010000434A1 (OSRAM)
CO (1) CO6280475A2 (OSRAM)
DK (1) DK2215047T3 (OSRAM)
ES (1) ES2443817T3 (OSRAM)
MX (1) MX2010004716A (OSRAM)
NZ (1) NZ585080A (OSRAM)
PL (1) PL2215047T3 (OSRAM)
PT (1) PT2215047E (OSRAM)
RU (1) RU2469728C2 (OSRAM)
WO (1) WO2009059188A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US20110207693A1 (en) * 2010-02-24 2011-08-25 Emisphere Technologies, Inc. Oral B12 Therapy
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
BR112020006841A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU4484997A (en) * 1996-09-18 1998-04-14 Thomas F. Brennan Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
MXPA01006297A (es) * 1998-12-28 2002-06-04 Biogentec Inc Tratamiento con cianocobalamina (vitamina b12) para enfermedades alergicas.
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
DE60017888T2 (de) 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
ES2386263T3 (es) * 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
HU229613B1 (en) 2001-06-01 2014-03-28 Novartis Ag Oral administration of parathyroid hormone and calcitonin
ATE443527T1 (de) 2001-08-17 2009-10-15 Novartis Pharma Gmbh 5-cnac zur oralen verabreichung von parathormonfragmenten
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
AR040737A1 (es) 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
WO2004024126A1 (en) * 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
CN100579955C (zh) 2003-04-04 2010-01-13 帝斯曼知识产权资产管理有限公司 N-烷氧基草酰丙氨酸酯的制备方法
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
JP2007525472A (ja) 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン(pth)含有医薬組成物
BRPI0412458A (pt) * 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
PL1651249T3 (pl) 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
EA013518B1 (ru) * 2004-05-06 2010-06-30 Эмисфире Текнолоджис, Инк. Кристаллические полиморфные формы n-[8-(2-гидроксибензоил)амино]каприлата натрия
CA2575706A1 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CN101296694A (zh) * 2005-11-04 2008-10-29 真塔公司 药物镓组合物和方法

Also Published As

Publication number Publication date
CL2010000434A1 (es) 2011-01-28
US20110293589A1 (en) 2011-12-01
JP5555634B2 (ja) 2014-07-23
BRPI0817396A2 (pt) 2015-04-07
JP2011502997A (ja) 2011-01-27
EP2215047B1 (en) 2013-11-20
RU2469728C2 (ru) 2012-12-20
EP2215047A1 (en) 2010-08-11
AU2008318423B2 (en) 2013-12-05
DK2215047T3 (da) 2014-02-03
CN101952241A (zh) 2011-01-19
CA2704780A1 (en) 2009-05-07
EP2215047A4 (en) 2010-11-10
US8288360B2 (en) 2012-10-16
WO2009059188A1 (en) 2009-05-07
ES2443817T3 (es) 2014-02-20
US8557792B2 (en) 2013-10-15
BRPI0817396C8 (pt) 2021-05-25
CN101952241B (zh) 2014-06-11
AU2008318423A1 (en) 2009-05-07
CA2704780C (en) 2014-06-10
KR20100126263A (ko) 2010-12-01
US8022048B2 (en) 2011-09-20
RU2010118423A (ru) 2011-12-10
NZ585080A (en) 2012-05-25
PT2215047E (pt) 2014-01-20
CO6280475A2 (es) 2011-05-20
US20130040910A1 (en) 2013-02-14
BRPI0817396B1 (pt) 2019-04-24
BRPI0817396B8 (pt) 2020-02-04
BRPI0817396C1 (pt) 2020-11-17
KR101344369B1 (ko) 2013-12-24
HK1146480A1 (en) 2011-06-10
US20100016255A1 (en) 2010-01-21
MX2010004716A (es) 2010-12-17

Similar Documents

Publication Publication Date Title
PT2215047E (pt) Processo para o tratamento da deficiência de vitamina b12
PL2148684T3 (pl) Sposób leczenia niedoboru i deficytu witaminy D
IL257418A (en) Methods for treating addiction
IL212348A0 (en) Treatment method
EP2313103A4 (en) PROCESS FOR TREATING A BLÉPHARITE
IL227641A0 (en) Methods for treating arthritis
ZA201707693B (en) Vitamin d3 and analogs thereof for treating alopecia
EP2032131A4 (en) Methods of Treatment
PL2301893T3 (pl) Sposób oczyszczania ścieku
IL200499A0 (en) Stabilization of vitamin b12
EP2144504A4 (en) METHOD FOR COMBATING BRAIN CANCER
IL200769A (en) A method for processing potash
IL238394A0 (en) Cancer treatment method
PT2393758E (pt) Processo de tratamento de águas residuais
GB0718684D0 (en) Treatment method
EP2144886A4 (en) METHOD OF TREATING MELANOMA
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
GB0610746D0 (en) Method of treatment
PT2509599E (pt) Processo para o tratamento de cancro pancreático
EP2203432A4 (en) PROCESSING METHOD
GB0723972D0 (en) Use of vitamin B12
GB0717337D0 (en) Method of treatment
GB0711228D0 (en) Treatment method
ZA201102198B (en) Treatment method
GB0823435D0 (en) Method of treatment